Jefferies reiterates argenx stock Buy rating after Q3 beat
Jefferies reiterated a Buy rating and $1,200 price target for argenx SE (ARGX) after its Q3 results. The company reported Vyvgart revenues of $1.7B, a 5% beat, and EPS of $7.80, in line with estimates. Operating expenses were higher due to the Forte deal. Analysts expect data readouts and revenue growth to drive future performance, with projections of $6.5B in FY2026 revenues. Other analysts have mixed price target adjustments.
How this was made
The 30-second read
Why it matters
The earnings beat and multiple analyst upgrades are likely to drive short-term buying pressure.
Market read
Positive earnings and analyst upgrades make ARGX a near-term bullish candidate.
What to watch
Operating expenses rose due to the Forte deal and a missed endpoint in a Phase 2/3 trial, which could weigh on margins.
Background
argenx SE (NASDAQ:ARGX) posted Q3 2026 results with Vyvgart revenue beating consensus and received upgraded price targets from several analysts.
Ticker impact
Jefferies reiterated a Buy rating and $1,200 price target after argenx reported Q3 revenue of $1.7B beating estimates.
likely upside as market prices in the revenue beat and higher price targets
Revenue beat, EPS in line, multiple analysts raised targets; the buy rating reinforces bullish bias.
Market effects
Biotech sector may see modest rally on strong specialty drug sales.
U.S. biotech stocks could benefit from positive earnings momentum.
Limited to investors tracking specialty pharma earnings.
Counterpoint
Revenue growth may be unsustainable if patient uptake slows; high valuation could limit upside.
Key entities
- AnalystJefferies
Reiterated Buy rating and $1,200 price target.
- AnalystTD Cowen
Maintained Buy rating with $1,353 price target.
